Upgrade to SI Premium - Free Trial

Simulations Plus (SLP) Tops Q4 EPS by 2c, Revenues Beat

November 16, 2020 4:09 PM

Simulations Plus (NASDAQ: SLP) reported Q4 EPS of $0.11, $0.02 better than the analyst estimate of $0.09. Revenue for the quarter came in at $9.5 million versus the consensus estimate of $9.38 million.

4QFY20 highlights compared with 4QFY19:

Shawn O’Connor, chief executive officer of Simulations Plus, said: “Simulations Plus achieved its goal of accelerating organic growth to 15-20%, overcoming headwinds from the COVID-19 pandemic due to continued strong growth from both our software and consulting revenue streams. Our future growth prospects were bolstered by a significant acquisition to expand our software business, growing our European presence, and the recent introductions of new software versions as well as the launch of several important collaborations. We continue to invest in R&D, funded both internally and from leading pharmaceutical and regulatory agencies, building on our leadership position in modelling and simulation for the drug development marketplace.”

John Kneisel, chief financial officer of Simulations Plus, added: “During the fourth quarter, we completed a strategic offering, issuing approximately 2.1 million shares and raising net proceeds of approximately $107.7 million. This follow-on offering gives the Company resources and scale to pursue additional acquisitions to further bolster our growth rates and broaden the value we can deliver to our clients. Once again, in the fourth quarter we benefited from tax deductions from stock compensation expense as employees took advantage of the increased value of their options. Overall, we continue to generate solid profitability and free cash flow, even after paying our regular quarterly dividend.”

For earnings history and earnings-related data on Simulations Plus (SLP) click here.

Categories

Corporate News Earnings Management Comments

Next Articles